Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Merck & Co., Inc. (MRK), headquartered in Rahway, New Jersey, is a major player in healthcare. Specializing in ...

Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases RAHWAY, N.J., September 24, 2024--(BUSINESS WIRE)--Merck Animal Health ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial ...

RAHWAY, N.J. - Merck Animal Health, a division of Merck & Co., Inc. (NYSE:MRK), has announced the release of a new vaccine, NOBIVAC NXT FeLV, to protect cats against feline leukemia virus (FeLV).

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...